Friday, March 14, 2014

Global markets for cardiac biomarkers to reach $7.2 billion by 2018

The World Health Organization estimates that more than 17.8 million deaths in 2008 were caused by heart disease, accounting for 30% of total global fatalities. Due to the acute nature and rapid progression of heart disease, a number of accurate and quantitative diagnostic assays have been developed to detect the presence of clinically proven biomarkers. New congestive heart failure biomarkers, approvals of stroke biomarkers, the growing market in point-of-care testing, and the rising awareness of medical care in China and other developing countries will drive significant growth in this market for the foreseeable future.

BCC Research provides an in-depth analysis of the global cardiac biomarker market through its report, Cardiac Biomarkers: Technologies and Global Markets. According to the report, this market was valued at $3.1 billion in 2012 and nearly $4 billion for 2013. BCC Research expects the market to grow to nearly $7.2 billion by 2018, and register a five-year compound annual growth rate of 12.8% from 2013 to 2018.

RSS Feeds – Biotechnology

Use this report to:

  • Gain an overview of the global market for biomarkers for cardiovascular disease and related technologies.
  • Analyze global market trends, with data from 2012 and 2013, and projections of CAGRs for the period 2013 to 2018.
  • Evaluate classifications of CVD by cerebrovascular, congestive, coronary, hypertensive, and peripheral arterial disease.
  • Assess the background and clinical values of cardiac biomarkers.
  • Review company profiles of major players in the industry.

To order your copy of this report (or any of its chapters) or to download the complimentary introduction chapter, click here.

No comments:

Post a Comment

Bookmark and Share